Joel Castro1,2, Luke Grundy1,2, Annemie Deiteren1,2, Andrea M Harrington1,2, Tracey O'Donnell1,2, Jessica Maddern1,2, Jessi Moore1,2, Sonia Garcia-Caraballo1,2, Grigori Y Rychkov2, Rilei Yu3, Quentin Kaas3, David J Craik3, David J Adams4, Stuart M Brierley1,2. 1. Visceral Pain Research Group, Human Physiology, Centre for Neuroscience, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042, Australia. 2. Centre for Nutrition and Gastrointestinal Diseases, Discipline of Medicine, University of Adelaide, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, 5000, Australia. 3. Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia. 4. Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Wollongong, NSW, 2522, Australia.
Abstract
BACKGROUND AND PURPOSE: Patients with irritable bowel syndrome suffer from chronic visceral pain (CVP) and limited analgesic therapeutic options are currently available. We have shown that α-conotoxin Vc1.1 induced activation of GABAB receptors on the peripheral endings of colonic afferents and reduced nociceptive signalling from the viscera. However, the analgesic efficacy of more stable, cyclized versions of Vc1.1 on CVP remains to be determined. EXPERIMENTAL APPROACH: Using ex vivo colonic afferent preparations from mice, we determined the inhibitory actions of cyclized Vc1.1 (cVc1.1) and two cVc1.1 analogues on mouse colonic nociceptors in healthy and chronic visceral hypersensitivity (CVH) states. Using whole-cell patch clamp recordings, we also assessed the inhibitory actions of these peptides on the neuronal excitability of colonic innervating dorsal root ganglion neurons. In vivo, the analgesic efficacy of these analogues was assessed by determining the visceromotor response to colorectal distension in healthy and CVH mice. KEY RESULTS: cVc1.1 and the cVc1.1 analogues, [C2H,C8F]cVc1.1 and [N9W]cVc1.1, all caused concentration-dependent inhibition of colonic nociceptors from healthy mice. Inhibition by these peptides was greater than those evoked by linear Vc1.1 and was substantially greater in colonic nociceptors from CVH mice. cVc1.1 also reduced excitability of colonic dorsal root ganglion neurons, with greater effect in CVH neurons. CVH mice treated with cVc1.1 intra-colonically displayed reduced pain responses to noxious colorectal distension compared with vehicle-treated CVH mice. CONCLUSIONS AND IMPLICATIONS: Cyclic versions of Vc1.1 evoked significant anti-nociceptive actions in CVH states, suggesting that they could be novel candidates for treatment of CVP. LINKED ARTICLES: This article is part of a themed section on Recent Advances in Targeting Ion Channels to Treat Chronic Pain. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc.
BACKGROUND AND PURPOSE:Patients with irritable bowel syndrome suffer from chronic visceral pain (CVP) and limited analgesic therapeutic options are currently available. We have shown that α-conotoxin Vc1.1 induced activation of GABAB receptors on the peripheral endings of colonic afferents and reduced nociceptive signalling from the viscera. However, the analgesic efficacy of more stable, cyclized versions of Vc1.1 on CVP remains to be determined. EXPERIMENTAL APPROACH: Using ex vivo colonic afferent preparations from mice, we determined the inhibitory actions of cyclized Vc1.1 (cVc1.1) and two cVc1.1 analogues on mouse colonic nociceptors in healthy and chronic visceral hypersensitivity (CVH) states. Using whole-cell patch clamp recordings, we also assessed the inhibitory actions of these peptides on the neuronal excitability of colonic innervating dorsal root ganglion neurons. In vivo, the analgesic efficacy of these analogues was assessed by determining the visceromotor response to colorectal distension in healthy and CVHmice. KEY RESULTS: cVc1.1 and the cVc1.1 analogues, [C2H,C8F]cVc1.1 and [N9W]cVc1.1, all caused concentration-dependent inhibition of colonic nociceptors from healthy mice. Inhibition by these peptides was greater than those evoked by linear Vc1.1 and was substantially greater in colonic nociceptors from CVHmice. cVc1.1 also reduced excitability of colonic dorsal root ganglion neurons, with greater effect in CVH neurons. CVHmice treated with cVc1.1 intra-colonically displayed reduced pain responses to noxious colorectal distension compared with vehicle-treated CVHmice. CONCLUSIONS AND IMPLICATIONS: Cyclic versions of Vc1.1 evoked significant anti-nociceptive actions in CVH states, suggesting that they could be novel candidates for treatment of CVP. LINKED ARTICLES: This article is part of a themed section on Recent Advances in Targeting Ion Channels to Treat Chronic Pain. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc.
Authors: Patrick A Hughes; Joel Castro; Andrea M Harrington; Nicole Isaacs; Melissa Moretta; Gareth A Hicks; David M Urso; Stuart M Brierley Journal: Gut Date: 2013-11-27 Impact factor: 23.059
Authors: Luke Grundy; Andrea M Harrington; Joel Castro; Sonia Garcia-Caraballo; Annemie Deiteren; Jessica Maddern; Grigori Y Rychkov; Pei Ge; Stefanie Peters; Robert Feil; Paul Miller; Andre Ghetti; Gerhard Hannig; Caroline B Kurtz; Inmaculada Silos-Santiago; Stuart M Brierley Journal: JCI Insight Date: 2018-10-04
Authors: Nestor N Jimenez-Vargas; Luke A Pattison; Peishen Zhao; TinaMarie Lieu; Rocco Latorre; Dane D Jensen; Joel Castro; Luigi Aurelio; Giang T Le; Bernard Flynn; Carmen Klein Herenbrink; Holly R Yeatman; Laura Edgington-Mitchell; Christopher J H Porter; Michelle L Halls; Meritxell Canals; Nicholas A Veldhuis; Daniel P Poole; Peter McLean; Gareth A Hicks; Nicole Scheff; Elyssa Chen; Aditi Bhattacharya; Brian L Schmidt; Stuart M Brierley; Stephen J Vanner; Nigel W Bunnett Journal: Proc Natl Acad Sci U S A Date: 2018-07-16 Impact factor: 11.205
Authors: Thomas Kremsmayr; Aws Aljnabi; Juan B Blanco-Canosa; Hue N T Tran; Nayara Braga Emidio; Markus Muttenthaler Journal: J Med Chem Date: 2022-04-14 Impact factor: 8.039
Authors: David T Wilson; Paramjit S Bansal; David A Carter; Irina Vetter; Annette Nicke; Sébastien Dutertre; Norelle L Daly Journal: Biomedicines Date: 2020-05-20
Authors: Adam C Kennedy; Alessia Belgi; Benjamin W Husselbee; David Spanswick; Raymond S Norton; Andrea J Robinson Journal: Toxins (Basel) Date: 2020-08-06 Impact factor: 4.546